Non-Small Cell Lung Cancer
Learn how sublobar resection showed "comparable oncologic outcomes and complication rates" as lobectomy per a recent review.
The FDA action date for its regulatory decision is anticipated during the third quarter of this year.
Dr. Liu shares his insights on the recent announcement that the phase 3 trial met its secondary endpoint of overall survival.
A team integrating clinical, dual-energy spectral computed tomography, and radiomics features into a predictive model.
The phase 2 trial included patients who had advanced or metastatic NSCLC with actionable genomic alterations.
Sunvozertinib is an irreversible EGFR inhibitor that targets a wide spectrum of EGFR mutations.
Glecirasib, also known as JAB-21822, is an oral, covalent KRAS G12C inhibitor.
For patients with NSCLC and EGFR mutations, amivantamab plus carboplatin-pemetrexed shows OS benefits versus chemo alone.
The improvement in median OS with the combination treatment is “expected to exceed one year," officials said.
The study showed there was “preliminary evidence of central nervous system-anti-tumor activity” in some patients.
Advertisement
Expert Interviews on Lung Cancer
Advertisement
Advertisement
Section Editor
Stephen V. Liu, MDThoracic Medical Oncologist | Georgetown University
Advertisement
Latest Lung Cancer News
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.